Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Minerva Cardiology and Angiology 2021 April;69(2) > Minerva Cardiology and Angiology 2021 April;69(2):215-21

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Cardiology and Angiology 2021 April;69(2):215-21

DOI: 10.23736/S2724-5683.20.05184-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

The coronary resorbable magnesium scaffold Magmaris®: what we have learnt (so far…)

Johan BENNETT 1, 2 , Keir McCUTCHEON 1, 2

1 Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; 2 Department of Cardiovascular Sciences, Katholieke Universiteit Leuven (KU Leuven), Leuven, Belgium



Bioresorbable scaffold (BRS) technology provides transient vessel support with drug-delivery capability without the long-term limitations of the permanent metallic drug-eluting stents (DES). Numerous scaffolds have been developed and investigated by device manufacturers, many of which, due to device deficiencies, have fallen by the wayside. This short review will focus on the resorbable magnesium scaffold Magmaris® the only metallic bioresorbable scaffold currently available, providing an evaluation of the most up to date clinical data whilst also briefly highlighting learning points regarding the ideal patient and lesion choice and optimal implantation technique.


KEY WORDS: Magnesium; Review; Technology

inizio pagina